JAK-IN-27

• UNSPSC Description:

  JAK-IN-27 (Compound 1) is a JAK inhibitor. JAK-IN-27 inhibits TYK2, JAK1, JAK2 with IC50s of 3.0, 7.7, 8.5 nM respectively. JAK-IN-27 inhibits IFN-α2b induced p-STAT3 in Jurkat cells (IC50: 23.7 nM)[1].

• Target Antigen:

  JAK

• Type:

  Reference compound

• Related Pathways:

  Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/jak-in-27.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C([C@H](C1)C1(F)F)N2[C@H]3CN(C[C@@H]2CC3)C4=NC(C(C=N5)=CN5C)=CN6C4=CC=N6

• Molecular Weight:

  413.42

• References & Citations:

  [1]Zhang P, et al. Preparation of pyrazolo[1,5-a]pyrazine derivatives and its use as JAK family kinase inhibitors. China, CN113150012 A. 2021-07-23.|[2]Zhang Panpan. Pyrazolo [1,5-a ] pyrazine derivative and preparation method and application thereof. Patent. CN113150012.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2673176-36-6